Equities research analysts at Kaufman Brothers lowered their price target on shares of NuVasive (NASDAQ: NUVA) from $21.00 to $15.00 in a research issued note to investors on Tuesday. They currently have a “hold” rating on the company’s shares.
Separately, analysts at Piper Jaffray (NYSE: PJC) reiterated an “overweight” rating on shares of NuVasive in a research note to investors on Thursday, November 3rd. Analysts at Rodman & Renshaw downgraded shares of NuVasive from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, November 1st. They now have a $33.00 price target on the stock. Also, analysts at RBC Capital (NYSE: RY) cut their price target on shares of NuVasive from $22.00 to $19.00 in a research note to investors on Monday, October 31st. They now have a “sector perform” rating on the stock.
NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine. During the year ended December 31, 2010, it marketed product portfolio focused onapplications for spine fusion surgery, including biologics. Its product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as offering of biologics, cervical and motion preservation products. NuVasive’s spine surgery product line offerings include products for the thoracolumbar spine, the cervical spine, and a set of motion preservation product offerings under development. Its biologic product line offerings include allograft (donated human tissue), FormaGraft, a collagen synthetic product used to aid the fusion process, and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells (MSCs). In October 2011, the Company acquired Impulse Monitoring, Inc.
Shares of NuVasive opened at 12.59 on Tuesday. NuVasive has a 52 week low of $11.02 and a 52 weekhigh of $34.91. The stock’s 50-day moving average is $13.03 and its 200-day moving average is $21.10. The company has a market cap of $531.9 million and a price-to-earnings ratio of 66.97.
Stay on top of analysts’ coverage with our daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day. Click here to register.
